

May 30, 2023



SUN
PHARMA

Current Price:

₹ 968.10

STOCK DATA

BSE Code	524715
NSE Symbol	SUNPHARMA
Reuters	SUN.BO
Bloomberg	SUNP IN

VALUE PARAMETERS

52 W H/L(Rs)	1071.90/789.75
Mkt. Cap.(Rs Cr)	232279.63
Latest Equity(Subscribed)	239.93
Latest Reserve (cons.)	55755.45
Latest EPS (cons.) -Unit Curr.	35.97
Latest P/E Ratio -cons	26.91
Latest Bookvalue (cons.) -Unit Curr.	233.38
Latest P/BV - cons	4.15
Dividend Yield -%	1.19
Face Value	1.00

SHARE HOLDING PATTERN (%)

Description as on	% of Holding 31/03/2023
Foreign	17.18
Institutions	19.25
Non Promoter Corp. Hold.	2.28
Promoters	54.48
Public & Others	6.82

Consolidated Financials Results

In Cr.

Particulars	Qtr Ending Mar. 23	Qtr Ending Mar. 22	Var. (%)
Net Sales	10725.57	9386.08	14
Other Operating Income	205.10	60.68	238
Other Income	373.28	113.59	229
Total Income	11303.95	9560.35	18
Total Expenditure	8299.99	11042.14	-25
PBIDT	3003.96	-1481.79	LP
Interest	92.74	37.34	148
PBDT	2911.22	-1519.13	LP
Depreciation	671.53	556.47	21
PBT	2239.69	-2075.60	LP
Tax	222.91	146.76	52
Reported Profit After Tax	2016.78	-2222.36	LP
Minority Interest After NP	-1.57	49.87	
Profit/Loss of Associate Company	-33.88	-5.02	
Net Profit after Minority Interest & P/L Asso.Co.	1984.47	-2277.25	LP
EPS	8.91	6.3	

Sun Pharmaceuticals Q4FY23 Results: the company reported net profit of Rs 1985 crore in Q4 FY23 as compared with net loss of Rs 2277 crore in corresponding quarter last year, in line with estimates

Highlights of Q4FY23 consolidated financials

- Gross sales at Rs. 10725.60 crores, growth of 14.3% vs Q4 last year.
- India formulation sales at Rs. 3364.10 crores, up 8.7% vs Q4 last year
- US formulation sales at US\$ 430 million, up 10.5% vs Q4 last year
- Global specialty sales at US\$ 244 million, including US\$6.8 million milestone received in Q4. Ex-milestone, up 28% vs Q4 last year.
- Global specialty sales, ex-milestone, accounted for 18.2% of Q4FY23 overall sales
- Emerging Markets formulation sales at US\$ 221 million, up 7.5% vs Q4 last year
- Rest of World formulation sales at US\$ 191 million, up 7.4% vs Q4 last year
- R&D investments at Rs. 665.70 crores compared to Rs. 543.30 crores for Q4 last year
- Operating Profit at Rs. 3003.96 crores, against operating loss of Rs,1481.79 crores vs Q4 last year. Operating margin improved for Q4 at 28.01% .
- Reported net profit for Q4FY23 was Rs. 1985 crores compared to net loss Rs. 2277 crores for Q4 last year.

India Business – Market Leadership

For the full year FY23, sales of formulations in India were 136,031 million, up by 6.6% over the same period last year. Excluding the covid-related product sales in the previous year, the sales growth for the FY23 was 10.2%. India Formulation sales were Rs. 33,641 million For Q4FY23, a

growth of 8.7% over Q4 last year and accounted for 31% of total consolidated sales for the quarter. Adjusting for the covid-related product sales in Q4FY22, the sales growth for the Q4FY23 was 9.8%. Sun Pharma holds 8.3% market share and is ranked No. 1 in the Rs. 1,850 Billion plus Indian pharmaceutical market as per AIOCD AWACS MAT March-2023 report. For Q4FY23, the company launched 24 new products in the Indian market.

US Formulations (including Taro)

Formulation sales in the US for the full year FY23 were US\$ 1,684 million up 10.3% over the same period last year. US formulation sales were US\$ 430 million for Q4FY23, a growth of 10.5% over Q4 last year and accounted for about 33% of total consolidated sales for the quarter.

Taro Performance

Taro's full year FY23 sales were US\$ 573 million, up about 2.1% over same period last year. Taro's reported net profit for FY23 was US\$ 25.4 million compared to US\$ 58.3 million. Taro posted Q4FY23 sales of US\$ 147 million, up by 2.3% YoY and net profit of about US\$ 6.9 million, lower by 74.7% over adjusted net profit of Q4 last year.

Emerging Markets

Formulation sales in Emerging Markets for the full year FY23 were US\$ 983 million, up 8.6% over the same period last year. Emerging Markets sales were US\$ 221 million for Q4FY23, a growth of 7.5% over Q4 last year and accounted for about 17% of total consolidated sales for the quarter.

Rest of World Markets

Formulation sales in Rest of World (RoW) markets, excluding US and Emerging Markets, for the full year FY23 were US\$ 752 million, up 2.7% over the same period last year. RoW market sales were US\$ 191 million for Q4FY23, a growth of 7.4% over Q4 last year and accounted for approximately 14.7% of total consolidated sales for the quarter.

Active Pharmaceutical Ingredients (API) – strategic strength

For the full year FY23, external API sales were at Rs. 19,724 million, up 7.5% over the same period last year. External sales of API were at Rs. 3,852 million for Q4FY23, lower by about 6.9% over Q4 last year. Our API business imparts benefits of vertical integration and continuity of supply chain for our formulations business.

Research – Investing for future

For the full year FY23, consolidated R&D investments were Rs. 23,676 million, or 5.5% of sales; while for Q4FY23 it stood at Rs. 6,657 million. Our R&D efforts span across both specialty and generic businesses and we continue to invest in building the pipeline for various markets including the US, Emerging Markets, RoW Markets and India. Our specialty R&D pipeline includes 5 molecules undergoing clinical trials. We have a comprehensive product offering in the US market consisting of approved ANDAs for 519 products while filings for 97 ANDAs await US FDA approval, including 28 tentative approvals.

On full year basis, the company's consolidated net profit of Rs surged 179.93% to Rs 10,503.4 crore in FY23 as compared with Rs 3752.1 crore in FY22. Net sales jumped 13.53% year on year to Rs 43,885.6 crore in FY23.

Management Comment

Dilip Shanghvi, Managing Director of the Company said, "I am pleased with well rounded growth demonstrated in FY23 by the company. Several of our businesses including Specialty, India and Emerging markets have continued to progress well. Our Specialty business remains on growth path and we are committed to continue scaling it up. Acquisition of Concert helps further strengthen our portfolio in dermatology. I believe deuruxolitinib can become a leading product to address highly unmet need in alopecia areata patients."

E-mail: researchfeedback@smcindiaonline.com



Corporate Office:
11/6B, Shanti Chamber,
Pusa Road, New Delhi - 110005
Tel: +91-11-30111000
www.smcindiaonline.com

Mumbai Office:
Lotus Corporate Park , A Wing 401 / 402 ,
4th Floor , Graham Firth Steel Compound ,
Off Western Express Highway, Jay Coach Signal,
Goreagon (East) Mumbai - 400063
Tel: 91-22-67341600, Fax: 91-22-28805606

Kolkata Office:
18, Rabindra Sarani,
Poddar Court, Gate No.- 4, 5th Floor, Kolkata-700001
Tel: 91-33-39847000, Fax: 91-33-39847004

Investments in securities market are subject to market risks, read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. The securities quoted are for illustration only and are not recommendatory. SMC is a SEBI registered Research Analyst having registration number INH100001849. CIN : L74899DL1994PLC063609.

SMC Global Securities Ltd. (hereinafter referred to as "SMC") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services and related activities. SMC is a registered member of National Stock Exchange of India Limited, Bombay Stock Exchange Limited, MSEI (Metropolitan Stock Exchange of India Ltd) and M/s SMC Comtrade Ltd is a registered member of National Commodity and Derivative Exchange Limited and Multi Commodity Exchanges of India and other commodity exchanges in India. SMC is also registered as a Depository Participant with CDSL and NSDL. SMC's other associates are registered as Merchant Bankers, Portfolio Managers, NBFC with SEBI and Reserve Bank of India. It also has registration with AMFI as a Mutual Fund Distributor.

SMC is a SEBI registered Research Analyst having registration number INH100001849. SMC or its associates has not been debarred/ suspended by SEBI or any other regulatory authority for accessing /dealing in securities market. SMC or its associates or its Research Analyst or his relatives do not hold any financial interest in the subject company interest at the time of publication of this Report. SMC or its associates or its Research Analyst or his relatives do not hold any actual/beneficial ownership of more than 1% (one percent) in the subject company, at the end of the month immediately preceding the date of publication of this Report. SMC or its associates its Research Analyst or his relatives does not have any material conflict of interest at the time of publication of this Report.

SMC or its associates/analyst has not received any compensation from the subject company covered by the Research Analyst during the past twelve months. The subject company has not been a client of SMC during the past twelve months. SMC or its associates has not received any compensation or other benefits from the subject company covered by analyst or third party in connection with the present Research Report. The Research Analyst has not served as an officer, director or employee of the subject company covered by him/her and SMC has not been engaged in the market making activity for the subject company covered by the Research Analyst in this report.

The views expressed by the Research Analyst in this Report are based solely on information available publicly available/internal data/ other reliable sources believed to be true. SMC does not represent/ provide any warranty expressly or impliedly to the accuracy, contents or views expressed herein and investors are advised to independently evaluate the market conditions/risks involved before making any investment decision. The research analysts who have prepared this Report hereby certify that the views /opinions expressed in this Report are their personal independent views/opinions in respect of the subject company.

Disclaimer: This Research Report is for the personal information of the authorized recipient and doesn't construe to be any investment, legal or taxation advice to the investor. It is only for private circulation and use. The Research Report is based upon information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied upon as such. No action is solicited on the basis of the contents of this Research Report. The Research Report should not be reproduced or redistributed to any other person(s) in any form without prior written permission of the SMC. The contents of this material are general and are neither comprehensive nor inclusive. Neither SMC nor any of its affiliates, associates, representatives, directors or employees shall be responsible for any loss or damage that may arise to any person due to any action taken on the basis of this Research Report. It does not constitute personal recommendations or take into account the particular investment objectives, financial situations or needs of an individual client or a corporate/s or any entity/s. All investments involve risk and past performance doesn't guarantee future results. The value of, and income from investments may vary because of the changes in the macro and micro factors given at a certain period of time. The person should use his/her own judgment while taking investment decisions. Please note that SMC its affiliates, Research Analyst, officers, directors, and employees, including persons involved in the preparation or issuance of this Research Report: (a) from time to time, may have long or short positions in, and buy or sell the securities thereof, of the subject company(ies) mentioned here in; or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company(ies) discussed herein or may perform or seek to perform investment banking services for such company(ies) or act as advisor or lender/borrower to such subject company(ies); or (c) may have any other potential conflict of interest with respect to any recommendation and related information and opinions. All disputes shall be subject to the exclusive jurisdiction of Delhi High Court.